8-K: Carmell Corporation Finalizes Acquisition of Elevai Skincare Business

Carmell Corporation has completed the acquisition of Elevai Skincare's business, expanding its product portfolio and commercial reach.

Summary

• Carmell Corporation has successfully acquired the skincare and haircare business of Elevai Skincare, Inc. through its subsidiary Cutis Cura Corporation.
• The acquisition was finalized on January 16, 2025, following an Asset Purchase Agreement dated December 31, 2024.
• The purchase price included approximately $1.4 million, consisting of 1,149,226 shares of Carmell common stock, 117,814 holdback shares, assumption of certain liabilities, and $56,525 in cash upon the sale of specific inventory.
• Additional earnout payments include 5% of net sales from Elevai's existing products annually for five years and a one-time $500,000 payment if hair and scalp product sales reach $500,000 within 24 months.
• Carmell acquired Elevai's product portfolio, commercial team, inventory worth approximately $1.0 million, and accounts receivable of approximately $0.03 million.
• Elevai's FY2024 revenue was approximately $2.5 million.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful acquisition, expected synergies, and expansion of the product portfolio. The financial terms appear reasonable, and the management commentary is optimistic. However, there are risks associated with integration and potential liabilities.

Positives

• The acquisition expands Carmell's bio-aesthetic product portfolio.
• It broadens Carmell's commercial footprint.
• The acquisition is expected to improve Carmell's cash flow.
• Carmell anticipates significant benefits from organizational synergies and overhead rationalization.
• The acquired business has a product portfolio with $2.5 million in revenue in FY2024.

Negatives

• The company is taking on the risk of unknown liabilities arising after the acquisition.
• Management's attention may be diverted from ongoing business operations due to the integration process.

Risks

• There are risks related to the ability to realize the anticipated benefits of the acquisition.
• The integration of Elevai's business may present challenges.
• There is a risk of unknown liabilities arising after the acquisition.
• The company faces risks related to the commercialization of its products and R&D pipeline.
• Changes in applicable laws or regulations could adversely affect the company.
• Economic, business, and competitive factors could negatively impact the company.

Future Outlook

Carmell expects to achieve significant benefits from organizational synergies and savings from overhead rationalization. The company also anticipates the acquisition will expand its product portfolio, broaden its commercial footprint, and improve its cash flow.

Management Comments

• Mr. Rajiv Shukla, Chairman of Carmell, stated that Carmell expects to achieve significant benefits from organizational synergies and savings from overhead rationalization.
• Mr. Shukla also noted that the transaction positively impacts Carmell in three key areas: expanding the bio-aesthetic product portfolio, broadening the commercial footprint, and improving cash flow.

Industry Context

This acquisition reflects a trend in the bio-aesthetics industry where companies are expanding their product portfolios and market reach through strategic acquisitions. Carmell's move to acquire Elevai's skincare and haircare business aligns with this trend, allowing them to leverage Elevai's existing products and technologies.

Comparison to Industry Standards

• The acquisition of a company with $2.5 million in revenue for approximately $1.4 million plus earnouts is within the range of typical valuations for early-stage companies in the skincare and haircare sector.
• Comparable companies in the bio-aesthetics space, such as those focused on exosome technology, often see similar acquisition structures with a mix of cash, stock, and earnout provisions.
• The 5% net sales earnout is a common mechanism to align the interests of the seller with the buyer's success in integrating the acquired business.
• The $500,000 milestone payment for achieving $500,000 in net revenue within 24 months is a typical performance-based incentive.

Stakeholder Impact

• Shareholders may benefit from the expanded product portfolio and potential revenue growth.
• Employees of both Carmell and Elevai may experience changes due to the integration.
• Customers may have access to a broader range of products.
• Suppliers may see changes in their relationships with the combined entity.
• Creditors may be impacted by the assumption of liabilities.

Next Steps

• Carmell will integrate Elevai's business into its operations.
• Carmell will work to realize the anticipated benefits of the acquisition.
• Carmell will focus on the launch and commercialization of its products.
• Carmell will file the required financial statements and pro forma financial information within 71 days.

Key Dates

Keywords

Acquisition, Skincare, Haircare, Bio-aesthetics, Elevai, Carmell, Asset Purchase, Exosomes, Net Sales, Earnout